Advertisement
Advertisement
U.S. markets open in 8 hours 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.61+0.27 (+3.68%)
At close: 04:00PM EST
7.61 0.00 (0.00%)
After hours: 04:02PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close7.34
Open7.28
Bid0.00 x 800
Ask0.00 x 800
Day's Range7.00 - 7.65
52 Week Range4.51 - 16.00
Volume414,113
Avg. Volume681,057
Market Cap931.175M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ERAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Erasca, Inc.
    Daily Spotlight: Important Inflation News Out TodayThe Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most-recent report (from September), PCE inflation was reported at 6.2% (the latest CPI report, from October, had inflation at 7.7%). At Argus, we forecast a rate of 5.9% for the October PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.1% in the last month. We expect the Core PCE to tick lower to 5.0% this month. Overall, inflation appears to have peaked during the summer and is starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 5.2% rate year-over-year, down from 6.8% last month and from 8.7% four months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.1%. That's down slightly from our 4.3% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing. Looking down the road, investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 3.1% and the five-year forward expectation rate at 2.3%.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

    ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed CTCSAs with Pfizer and Eli Lilly to evaluate encorafenib and cetuximab in combination with ERAS-007 SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patient

  • GlobeNewswire

    Erasca to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that company management will present at the following investor conferences: 5th Annual Evercore ISI HealthCONx Conference (November 29 – December 1, Virtual) Format: Fireside Chat Date and Time: Tuesday, November 29, 8:50 – 9:10 AM EST We

  • GlobeNewswire

    Erasca Reports Third Quarter 2022 Financial Results and Business Updates

    Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer to supply palbociclib in combination with ERAS-007; signed strategic R&D collaboration with MD Anderson Strong balance sheet with cash, cash equivalents, and marketable securities of $365 million SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision

Advertisement
Advertisement